Post Depomed Deal Flop, Horizon Buys Crealta For $510m
This article was originally published in Scrip
Horizon Pharma plc has moved on from its failed $1.7bn attempt to buy Depomed Inc. with the $510m cash purchase of Crealta Holdings LLC, which bought the developer of specialty gout drug Krystexxa (pegloticase) out of bankruptcy two years ago for $120.4m.
You may also be interested in...
With US FDA action on teprotumumab anticipated in March, Horizon has assembled a 100-person commercial team to begin educating physicians and payers on the rare autoimmune condition thyroid eye disease (TED).
Horizon will boost its orphan drug business through the acquisition of Raptor, using a combination of debt and cash from its primary care and other assets to fund the transaction.
Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.